Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment

F Piñero, M Dirchwolf, MG Pessôa - Cells, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Inflammation and liver cancer: molecular mechanisms and therapeutic targets

YM Yang, SY Kim, E Seki - Seminars in liver disease, 2019 - thieme-connect.com
Hepatocellular carcinoma (HCC) is associated with chronic inflammation and fibrosis arising
from different etiologies, including hepatitis B and C and alcoholic and nonalcoholic fatty …

[HTML][HTML] The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?

X Hu, R Chen, Q Wei, X Xu - International Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has been
acknowledged as a leading cause of death among cirrhosis patients. Difficulties in early …

microRNA‐based diagnostic and therapeutic applications in cancer medicine

LF Sempere, AS Azmi, A Moore - Wiley Interdisciplinary …, 2021 - Wiley Online Library
It has been almost two decades since the first link between microRNAs and cancer was
established. In the ensuing years, this abundant class of short noncoding regulatory RNAs …

[HTML][HTML] New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma

T Wang, KH Zhang - Frontiers in Oncology, 2020 - frontiersin.org
An early diagnosis of hepatocellular carcinoma (HCC) followed by effective treatment is
currently critical for improving the prognosis and reducing the associated economic burden …

Overview upon miR-21 in lung cancer: focus on NSCLC

C Bica-Pop, R Cojocneanu-Petric, L Magdo… - Cellular and Molecular …, 2018 - Springer
Considering the high mortality rate encountered in lung cancer, there is a strong need to
explore new biomarkers for early diagnosis and also improved therapeutic targets to …

Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage

P Luo, S Wu, Y Yu, X Ming, S Li, X Zuo, J Tu - Pathology & Oncology …, 2020 - Springer
Hepatocellular carcinoma (HCC) is one of the most malignant cancer with high morbidity
and mortality which lead to a serious burden to society. AFP (alpha-fetoprotein) is the most …

Molecular and functional roles of microRNAs in the progression of hepatocellular carcinoma—a review

K Oura, A Morishita, T Masaki - International journal of molecular sciences, 2020 - mdpi.com
Liver cancer is the fourth leading cause of cancer deaths globally, of which hepatocellular
carcinoma (HCC) is the major subtype. Viral hepatitis B and C infections, alcohol abuse, and …

m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression

D Rong, F Wu, C Lu, G Sun, X Shi, X Chen… - … Therapy-Nucleic Acids, 2021 - cell.com
N6-methyladenosine (m6A) is capable of mediating circRNA generation in carcinoma
biology. Nevertheless, the posttranscriptional systems of m6A and circRNA in hepatocellular …

MicroRNAs in the pathogenesis of hepatocellular carcinoma: a review

A Morishita, K Oura, T Tadokoro, K Fujita, J Tani… - Cancers, 2021 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is one of the most frequently occurring
cancers, and the prognosis for late-stage HCC remains poor. A better understanding of the …